Boehringer Ingelheim
Boehringer Ingelheim
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Boehringer Ingelheim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:54 UTC. Showing 200 of 992. Open this list on ClinicalTrials.gov
- N/ANCT03405363 · Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 AgonistsBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph1NCT03343678 · This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxBoehringer Ingelheim · withdrawn · Leukemia, Lymphocytic, Chronic, B-Cell · study chair
- N/ANCT03258645 · This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a StrokeBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph2NCT03230097 · This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 YearBoehringer Ingelheim · terminated · Psychotic Disorders · study chair
- Ph1NCT03135899 · BI 443651 Methacholine ChallengeBoehringer Ingelheim · completed · Asthma · study chair
- Ph1NCT03116906 · Safety and Tolerability of BI 685509 in Healthy SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT03099174 · This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerBoehringer Ingelheim · completed · Neoplasms, Breast Neoplasms · study chair
- Ph1NCT03100903 · Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT03092752 · Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDVBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph1NCT03086356 · Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady StateBoehringer Ingelheim · completed · Healthy Volunteers · study chair
- N/ANCT03075449 · Real World Data on Management of Male LUTSBoehringer Ingelheim · completed · Benign Prostatic Hyperplasia · study chair
- N/ANCT03074149 · Investigating Idiopathic Pulmonary Fibrosis in GreeceBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph1NCT03074162 · Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT03064841 · Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in ChinaBoehringer Ingelheim · completed · Type 2 Diabetes Mellitus · study chair
- Ph3NCT03057951 · EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)Boehringer Ingelheim · completed · Heart Failure · study chair
- Ph3NCT03057977 · EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)Boehringer Ingelheim · completed · Heart Failure · study chair
- Ph4NCT03055988 · Cardiovascular Function in COPD PatientsBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT03050619 · Characteristics of Empagliflozin InitiatorsBoehringer Ingelheim · completed · Type 2 Diabetes · study chair
- N/ANCT03030638 · Drug Utilization Study for OlodaterolBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT03021265 · To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With HypertensionBoehringer Ingelheim · completed · Hypertension · study chair
- Ph1NCT03004404 · To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy Volunteers · study chair
- N/ANCT03003494 · Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - ItalyBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph3NCT03003000 · Ibuprofen/Caffeine Lower Back or Neck Pain StudyBoehringer Ingelheim · completed · Back Pain, Neck Pain · study chair
- Ph1NCT02999191 · Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male SubjectsBoehringer Ingelheim · completed · Healthy Volunteers · study chair
- Ph2NCT03000075 · BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque PsoriasisAbbVie · completed · Psoriasis · study chair
- Ph3NCT02999178 · Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)Boehringer Ingelheim · completed · Lung Diseases, Interstitial · study chair
- N/ANCT02982863 · Treatment Pattern of Oral Anticoagulants (OAC) in JapanBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph1NCT02978690 · Spesolimab (BI 655130) Single Dose in Generalized Pustular PsoriasisBoehringer Ingelheim · completed · Psoriasis · study chair
- Ph1NCT02976519 · BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF SubjectsBoehringer Ingelheim · completed · Cystic Fibrosis · study chair
- Ph1NCT02969317 · Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD PatientsBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph1NCT02963701 · Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy SubjectsBoehringer Ingelheim · completed · Healthy Volunteers · study chair
- Ph1NCT02952248 · A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursBoehringer Ingelheim · completed · Neoplasms · study chair
- N/ANCT02946931 · All-Case Surveillance of Prizbind®Boehringer Ingelheim · completed · Hemorrhage · study chair
- Ph3NCT02930837 · Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke OnsetBoehringer Ingelheim · completed · Stroke · study chair
- N/ANCT02927795 · OTIVACTO Spain Non Interventional StudyBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph3NCT02913326 · A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)Boehringer Ingelheim · completed · Thromboembolism · study chair
- N/ANCT02910167 · Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan LimaBoehringer Ingelheim · completed · Acute Pain, Dysmenorrhea · study chair
- Ph1NCT02899338 · Pharmacokinetics and Safety of BI 695501Boehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02897349 · Linagliptin Add-on to Insulin Background TherapyBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph1NCT02891148 · Single Rising Dose Study of BI 690517 in Healthy VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02871635 · BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and ImmunogenicityBoehringer Ingelheim · completed · Crohn Disease · study chair
- N/ANCT02864914 · Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 InhibitorsBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- N/ANCT02864407 · Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary DiseaseBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph1NCT02854527 · Transporter Cocktail Mutual InteractionBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02853136 · Influence of Fluvoxamine on the Pharmacokinetics of BI 409306Boehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02852824 · Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph4NCT02853123 · Effect of Tiotropium + Olodaterol on Breathlessness in COPD PatientsBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph3NCT02850965 · Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque PsoriasisBoehringer Ingelheim · completed · Psoriasis · study chair
- N/ANCT02850978 · Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary DiseaseBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT02848833 · JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- N/ANCT02849509 · Patient Convenience Study- NIS RELATEBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- N/ANCT02839746 · Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)Boehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph3NCT02831660 · CU Programme of Idarucizumab for Japanese PatientsBoehringer Ingelheim · completed · Hemorrhage · study chair
- Ph3NCT02831569 · Japanese IP-TN TrialBoehringer Ingelheim · completed · Pain · study chair
- Ph2NCT02832037 · Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in SchizophreniaBoehringer Ingelheim · completed · Schizophrenia · study chair
- Ph1NCT02821910 · Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single TabletsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02815644 · Empa/Lina FDC Food Effect Study (Japan)Boehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02815670 · Reversal Dabigatran Anticoagulant Effect With IdarucizumabBoehringer Ingelheim · completed · Hemorrhage · study chair
- N/ANCT02803580 · IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph3NCT02802345 · Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function ImpairmentBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- N/ANCT02798107 · Observational Study to Evaluate Safety of Idarucizumab in Pediatric PatientsBoehringer Ingelheim · withdrawn · Hemorrhage · study chair
- Ph4NCT02788474 · Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph2NCT02788513 · BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.Boehringer Ingelheim · completed · Alzheimer Disease · study chair
- N/ANCT02785354 · Anticoagulants Comparative Benefit-risk Ratio in Real LifeBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph1NCT02783040 · Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and DigoxinBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02782624 · Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02780700 · Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]Boehringer Ingelheim · terminated · Colorectal Neoplasms · study chair
- Ph2NCT02780687 · Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based ChemotherapyBoehringer Ingelheim · completed · Urologic Neoplasms · study chair
- Ph3NCT02776683 · Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal CancerBoehringer Ingelheim · completed · Colorectal Neoplasms · study chair
- Ph2NCT02770170 · Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus NephritisBoehringer Ingelheim · completed · Lupus Nephritis · study chair
- Ph1NCT02759016 · Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With IbrutinibBoehringer Ingelheim · completed · Leukemia, Lymphocytic, Chronic, B-Cell · study chair
- Ph1NCT02758171 · Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT02755181 · fMRI in ImpulsivityBoehringer Ingelheim · completed · Impulse Control Disorders, Borderline Personality Disorder · study chair
- N/ANCT02751879 · Real World Data on Gi(l)Otrif® Dose AdjustmentBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT02751385 · Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerBoehringer Ingelheim · terminated · Carcinoma, Non-Small-Cell Lung · study chair
- Ph2NCT02732951 · Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular EdemaBoehringer Ingelheim · completed · Macular Edema · study chair
- Ph1NCT02733627 · To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 DaysBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02722135 · A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy FailedBoehringer Ingelheim · withdrawn · Leukemia, Myeloid, Acute · study chair
- Ph1NCT02722161 · Olmutinib (BI 1482694) ADME StudyBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT02722174 · Fingerprinting of ImpulsivityBoehringer Ingelheim · completed · Impulse Control Disorders · study chair
- Ph1NCT02721875 · Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic SyndromesBoehringer Ingelheim · terminated · Myelodysplastic Syndromes · study chair
- N/ANCT02720757 · Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)Boehringer Ingelheim · terminated · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT02719639 · OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)Boehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph2NCT02719171 · BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisAbbVie · completed · Arthritis, Psoriatic · study chair
- N/ANCT02719184 · Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)Boehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema · study chair
- Ph1NCT02710630 · Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02706925 · To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02702011 · Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 1 · study chair
- Ph3NCT02700815 · Capsaicin + Diclofenac Gel in Acute Back Pain or Neck PainBoehringer Ingelheim · completed · Acute Pain · study chair
- Ph1NCT02696616 · Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph4NCT02695290 · Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)Boehringer Ingelheim · terminated · Carcinoma, Non-Small-Cell Lung, ErbB Receptors · study chair
- Ph3NCT02694523 · BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisAbbVie · completed · Psoriasis · study chair
- Ph1NCT02694354 · Investigation of Single Rising Doses of BI 685509Boehringer Ingelheim · completed · Healthy · study chair
- N/ANCT02689492 · SATisfaction and Adherence to COPD TreatmentBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph1NCT02689505 · Weekly BI 836880 in Patients With Advanced Solid TumorsBoehringer Ingelheim · completed · Neoplasms · study chair
- Ph3NCT02684357 · BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisAbbVie · completed · Psoriasis · study chair
- Ph3NCT02684370 · BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisAbbVie · completed · Psoriasis · study chair
- N/ANCT02684981 · Patient Convenience Study (RE-SONANCE)Boehringer Ingelheim · completed · Atrial Fibrillation, Stroke · study chair
- Ph4NCT02683109 · Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPDBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT02675517 · Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical PracticeBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph1NCT02674152 · Dose Finding Study of BI 836880 in Patients With Solid TumorsBoehringer Ingelheim · completed · Neoplasms · study chair
- Ph3NCT02672852 · BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentAbbVie · completed · Psoriasis · study chair
- N/ANCT02671422 · LUME BioNIS: a Biomarker Study in Patients With NSCLCBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT02668393 · Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT02667704 · Influence of Bosentan on the Pharmacokinetics of NintedanibBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02657408 · Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus PlaceboBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02652416 · Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02642614 · Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPDBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- Ph3NCT02640612 · Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid ArthritisBoehringer Ingelheim · completed · Arthritis, Rheumatoid · study chair
- Ph2NCT02636907 · Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled SyringeBoehringer Ingelheim · completed · Arthritis, Rheumatoid · study chair
- Ph1NCT02635750 · Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1/Ph2NCT02632721 · A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)Boehringer Ingelheim · completed · Leukemia, Myeloid, Acute · study chair
- Ph2NCT02632747 · Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyBoehringer Ingelheim · completed · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity · study chair
- Ph3NCT02629965 · Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD PatientsBoehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT02631057 · Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in JapanBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph1NCT02629354 · To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another TabletBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02624492 · To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLBoehringer Ingelheim · completed · Lymphoma, Large B-Cell, Diffuse · study chair
- N/ANCT02607722 · All-Case Surveillance of Ofev in Patients With IPF in JapanBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph4NCT02606877 · A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph1NCT02606903 · Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or AutoinjectorBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02597998 · Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02597946 · Afatinib in NSCLC With HER2 MutationBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph3NCT02597933 · A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisBoehringer Ingelheim · completed · Scleroderma, Systemic · study chair
- N/ANCT02597920 · Patient Convenience StudyBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- N/ANCT02596230 · RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous ThromboembolismBoehringer Ingelheim · completed · Venous Thromboembolism · study chair
- Ph1NCT02596217 · Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male VolunteersAbbVie · completed · Healthy · study chair
- Ph4NCT02589639 · Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph4NCT02589626 · Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RABoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph3NCT02580591 · Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)Boehringer Ingelheim · completed · Diabetes Mellitus, Type 1 · study chair
- Ph4NCT02579603 · Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFBoehringer Ingelheim · completed · Idiopathic Pulmonary Fibrosis · study chair
- Ph1
- Ph1NCT02574845 · DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)Boehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02572752 · Relative Bioavailability of 2 Oral Formulations of NintedanibBoehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02573311 · Actual Use Study of Tamsulosin in MenBoehringer Ingelheim · completed · Urological Manifestations · study chair
- Ph1NCT02572609 · Relative Bioavailability Study Between Two Formulations Containing Ambroxol HydrochlorideBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02525679 · Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02516553 · BI 894999 First in Human Dose Finding Study in Advanced MalignanciesBoehringer Ingelheim · completed · Neoplasms, NUT Carcinoma · study chair
- Ph1NCT02516098 · Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.Boehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02514239 · Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma PatientsBoehringer Ingelheim · completed · Multiple Myeloma · study chair
- Ph4NCT02514174 · Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung, ErbB Receptors · study chair
- Ph1NCT02513446 · Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT02489981 · Specific Use-result Surveillance of Spiriva Respimat in AsthmaticsBoehringer Ingelheim · completed · Asthma · study chair
- N/ANCT02489942 · Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph3NCT02489968 · Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- N/ANCT02483416 · Evaluation of the Impact of Nurse-led Telephone on Treatment ComplianceBoehringer Ingelheim · terminated · Carcinoma, Non-Small-Cell Lung · study chair
- Ph3NCT02453555 · Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph2NCT02443298 · Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent AsthmaAbbVie · completed · Asthma · study chair
- N/ANCT02440854 · Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care SettingsBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT02438683 · BI 409306 Cardiac Safety Trial in Healthy VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02438696 · Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- N/ANCT02433366 · Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial FibrillationBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph1NCT02417831 · Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.Boehringer Ingelheim · completed · Prostatic Hyperplasia · study chair
- Ph1NCT02417844 · Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.Boehringer Ingelheim · completed · Prostatic Hyperplasia · study chair
- Ph3NCT02417129 · BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular LymphomaBoehringer Ingelheim · terminated · Lymphoma, Non-Hodgkin · study chair
- Ph3NCT02414958 · Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)Boehringer Ingelheim · completed · Diabetes Mellitus, Type 1 · study chair
- Ph1NCT02392468 · Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy VolunteersBoehringer Ingelheim · completed · Schizophrenia, Alzheimer Disease · study chair
- N/ANCT02392455 · VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)Boehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- N/ANCT02392481 · Asthma Biomarker StudyBoehringer Ingelheim · completed · Asthma · study chair
- Ph1NCT02383888 · Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1/Ph2NCT02372006 · Trial of Afatinib in Pediatric TumoursBoehringer Ingelheim · completed · Neuroectodermal Tumors, Rhabdomyosarcoma · study chair
- N/ANCT02367131 · Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes MellitusBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- Ph1NCT02362516 · Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809Boehringer Ingelheim · completed · Healthy · study chair
- Ph4NCT02348723 · Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)Boehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph1NCT02345304 · Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and DigoxinBoehringer Ingelheim · withdrawn · Healthy · study chair
- Ph1NCT02342717 · Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02337907 · BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.Boehringer Ingelheim · completed · Alzheimer Disease · study chair
- Ph1NCT02337283 · Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)Boehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02331277 · Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02305901 · The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02300311 · Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back PainBoehringer Ingelheim · completed · Low Back Pain · study chair
- Ph1NCT02300298 · Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph3NCT02296138 · Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.Boehringer Ingelheim · completed · Pulmonary Disease, Chronic Obstructive · study chair
- N/ANCT02285361 · GIOTRIF rPMS in Korean Patients With NSCLCBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph2NCT02281773 · A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.Boehringer Ingelheim · completed · Schizophrenia · study chair
- Ph1NCT02273388 · BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid TumoursBoehringer Ingelheim · completed · Neoplasms · study chair
- Ph3NCT02272413 · Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung CancerBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT02266472 · Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and FemaleBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02254148 · The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)Boehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02254161 · Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female VolunteersBoehringer Ingelheim · terminated · Healthy · study chair
- Ph1NCT02248259 · Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor MetabolizersBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02240693 · Alzheimer Disease Proof of Concept Study With BI 409306 Versus PlaceboBoehringer Ingelheim · completed · Alzheimer Disease · study chair
- Ph2NCT02240706 · Phase I/II Trial to Investigate BI 836858 in Myelodysplastic SyndromesBoehringer Ingelheim · terminated · Myelodysplastic Syndromes · study chair
- N/ANCT02240667 · Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)Boehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph4NCT02240680 · Linagliptin as Add on to Basal Insulin in the ElderlyBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
- N/ANCT02240654 · Evaluation of Potential Off-label Use of Dabigatran Etexilate in EuropeBoehringer Ingelheim · completed · Atrial Fibrillation · study chair
- Ph3NCT02239120 · Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)Boehringer Ingelheim · completed · Stroke, Secondary Prevention · study chair
- Ph1NCT02231931 · Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and RosuvastatinBoehringer Ingelheim · completed · Healthy · study chair
- Ph3NCT02231164 · LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchBoehringer Ingelheim · terminated · Carcinoma, Non-Small-Cell Lung · study chair
- N/ANCT02230982 · Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisBoehringer Ingelheim · no longer available · Idiopathic Pulmonary Fibrosis · study chair
- Ph1NCT02230995 · Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02225626 · Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male SubjectsBoehringer Ingelheim · completed · Healthy · study chair
- Ph2NCT02223260 · Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of AgeBoehringer Ingelheim · completed · Venous Thromboembolism · study chair
- Ph1NCT02222168 · Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph4NCT02208843 · Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationBoehringer Ingelheim · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph2NCT02203851 · Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque PsoriasisAbbVie · completed · Psoriasis · study chair
- Ph1NCT02204072 · BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)Boehringer Ingelheim · completed · Prostatic Neoplasms, Castration-Resistant · study chair
- Ph1NCT02202512 · Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy VolunteersBoehringer Ingelheim · completed · Healthy · study chair
- Ph1NCT02201329 · Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaBoehringer Ingelheim · completed · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic · study chair
- Ph3NCT02197416 · Safety of Dabigatran Etexilate in Blood Clot Prevention in ChildrenBoehringer Ingelheim · completed · Venous Thromboembolism, Secondary Prevention · study chair
- N/ANCT02197078 · Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of LinagliptinBoehringer Ingelheim · completed · Diabetes Mellitus, Type 2 · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.